Profit margins for RLG's existing product mix are clearly still...

Profit margins for RLG's existing product mix are clearly still too small for the company to achieve profitability.

The recent growth in the RLG/AFT online pharma business in China is promising as retail margins for these products are high, but it remains to be seen what sales volumes can be achieved.

There has been much promotion of the Santander relationship and more recently the collaboration with the UK's FDEA trade association, but no new business / client win has been announced as yet. Retail margins for food and beverage products are high so there is potential here if they can secure a decent brand for sale into the Chinese market.

There is potential for very high margins on Vora protein powders / supplements, but there has been no meaningful update on the status of this business since its initial announcement.

The sheer size of the Chinese consumer market means there is always potential for a single product to deliver a breakthrough for RLG, but the wait continues for shareholders.

All IMO and GLTAH.